Strikingly, we found that the estimated proportion of GPNMB+ MDMs independently indicated a worse outcome in GBM patients, whereas ICAM1+ MDMs demonstrated a better prognosis (Fig. 2C). This evidence concerns the gene ICAM1 and glioblastoma.